10x Genomics Inc. can’t dodge Parse Biosciences Inc.'s petition to invalidate one of its patents aimed at analyzing nucleic acids from cells.
The US Patent and Trademark Office’s administrative tribunal agreed to institute inter partes review of US Patent No. 10,155,981 in an Oct. 13 decision, saying Parse sufficiently alleged that the patent examiner erred by failing to wholly consider the teachings in a scientific journal.
10x sued Parse in August 2022 for allegedly infringing six patents. Parse has since petitioned to invalidate all six while the lawsuit in the US District Court for the District of Delaware progresses. The ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.